Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events.,Liver International

当前位置： X-MOL 学术 › Liver Int. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events.
Liver International ( IF 6.7 ) Pub Date : 2020-05-25 , DOI: 10.1111/liv.14496
Changhoon Yoo ₁ , Seonggyu Byeon _{2,

3} , Yeonghak Bang ₁ , Jaekyung Cheon ₄ , Jin W Kim ₅ , Jee H Kim ₅ , Hong J Chon ₆ , Beodeul Kang ₆ , Myoung J Kang ₇ , Ilhwan Kim ₇ , Jun-Eul Hwang ₈ , Jung H Kang ₉ , Myung A Lee ₁₀ , Jung Y Hong ₂ , Ho Y Lim ₂ , Baek-Yeol Ryoo ₁

Affiliation

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
Division of Hematology-Oncology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Division of Hematology-Oncology, Department of Internal Medicine, Bundang CHA Hospital, Seongnam, Korea.
Division of Oncology, Department of Internal Medicine, Inje University College of Medicine, Haeundae Paik Hospital, Busan, Korea.
Division of Hematology-Oncology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University, Jinju, Korea.
Division of Hematology-Oncology, Department of Internal Medicine, Seoul St. Mary's hospital, The Catholic University of Korea, Seoul, Korea.

Regorafenib demonstrated a clinical benefit for patients with unresectable hepatocellular carcinoma (uHCC) in the phase III RESORCE trial. Considering the heterogeneity of uHCC and discrepancies in its characteristics between prospective trials and daily practice, real‐life evidence is necessary.

中文翻译：